Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

1. Berenbaum, F.
2. Blanco, F.J.
3. Guermazi, A.
4. Miki, K.
5. Yamabe, T.
6. Viktrup, L.
7. Junor, R.
8. Carey, W.
9. Brown, M.T.
10. West, C.R.
11. Verburg, K.M.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1136/ANNRHEUMDIS-2019-216296 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus